ACTRN12613000741785终止未知
An unblinded, randomised, controlled trial to assess the care given to patients, who have been referred to a nephrologist, and, assess the outcomes of standard outpatient care and telephone consultation care group.
ambour General Hospital0 个研究点目标入组 60 人开始时间: 2013年7月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 终止
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1.Patient referred to the SCHHS renal service and triaged (as per triage guidelines) as category 2 or 3
- •2.Age >18
- •3.Patient able to give informed consent
- •4.GP gives informed consent
排除标准
- •1.Patient or GP declines consent for the study
- •2.Specialist or GP decision on clinical grounds that standard care would be more appropriate
- •3.Interpreter required
- •4.Severe cognitive impairment
- •5.Pregnant
研究者
相似试验
尚未招募
4 期
A randomised, blinded, controlled trial of silicone disposable laryngeal masks during anaesthesia in spontaneously breathing adult patientsACTRN12607000346471Investigator initiated (Dr. Daryl Williams)120
已完成
不适用
Single-blind, randomized controlled trial to assess the effect of blue-light alleviation on visual fatigue in healthy volunteershealthy volunteersJPRN-UMIN000033825Minamiaoyama Eye Clinic60
已完成
3 期
Efficacy and safety of a fixed dose combination of Glycopyrronium/Formoterol/Fumarate/Fluticasone Propionate dry powder inhaler in patients with chronic obstructive pulmonary disease.CTRI/2019/01/017156Glenmark Pharmaceuticals Ltd396
已完成
3 期
A randomised, controlled clinical trial assessing the efficacy of;Lanreotide to halt disease progression in ADPKDpolycystic kidney disease100383601001965410029149Autosomal Dominant Polycystic Kidney DiseaseNL-OMON39497niversitair Medisch Centrum Groningen300
进行中（未招募）
不适用
To investigate the effect of Lanreotide on renal function decline in ADPKD patientsFirst, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measuredby change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotidemodifies progression of the liver phenotype in the subset of ADPKD patients with moderate to severe polycystic liverdisease as measured by change in liver volume.MedDRA version: 14.1Level: LLTClassification code 10023433Term: Kidney polycysticSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-005017-37-NLDIPAK Consortium